We previously reported that immunohistochemically-determined MSLN expression is a strong independent prognostic factor in stage II/III CRC when standard sections are used and that the MSLN expression detected in tumors exhibited only limited heterogeneity [13, 14]. This evidence concerns the gene MSLN and colorectal carcinoma.